Search
forLearn
5 / 801 resultslearn ORPL
learn oligopeptide-71
learn Lupine protein
learn 2-deoxy-D-Ribose
Research
5 / 66 results
research Structural Abnormalities in the Hair of a Patient with a Novel Ribosomopathy
The patient's hair was thinner and had fewer lipids due to a genetic mutation.
research Human gene correlation analysis (HGCA): A tool for the identification of transcriptionally co-expressed genes
The HGCA tool helps identify genes that work together by analyzing their co-expression patterns.
research A new tool for conditional gene manipulation in a subset of keratin‐expressing epithelia
The Megsin-Cre transgene is a new tool for genetic manipulation in the skin and upper digestive tract.
research Generating detailed intercellular communication patterns in psoriasis at the single-cell level using social networking, pattern recognition, and manifold learning methods to optimize treatment strategies
New insights into cell communication in psoriasis suggest innovative drug treatments.
research Abstracts from the 55th European Society of Human Genetics (ESHG) Conference: Oral Presentations
NIPT can help detect potential maternal cancer, and GIPXplore can identify immune diseases in pregnancies.
Community Join
5 / 1000+ resultscommunity Proof DHT is not the main cause of hair loss. TRPS1 Gene and Protein might be. PP405 won’t work. AMP-303 might!
Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.
community The story of RU58841/ PSK3841
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
community IGFBP‐rP1 is a potential therapeutic target in androgenic alopecia
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
community The story of RU58841/PSK3841
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
community Having Ru58841 mailed to my house
RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.